TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Cycle 1:~* Patient is scheduled to receive his/her first course of cisplatin chemotherapy at a dose of at least 70 mg/m\^2 administered a maximum of 3 hours~* Patient has a predicted life expectancy of at least 3 months~* Patient is not pregnant~Cycle 2 (optional):~* Participation in the study during the next cycle of chemotherapy is considered~appropriate by the investigator and will not pose unwarranted risk to the patient.~* Satisfactory completion of the preceding cycle of chemotherapy and related~study procedures.~* Patient will continue to receive the same chemotherapy regimen as in Cycle 1. The cisplatin dose may be reduced in subsequent cycle, as long as the new~dose is still no less than 70 mg/m\^2.~Exclusion Criteria:~Cycles 1 \& 2:~* Patient will receive stem cell therapy in conjunction with cisplatin~* Patient has an active infection or any uncontrolled disease (e.g. diabetes)~* Patient will receive multiple-day chemotherapy with cisplatin~* Patient will receive chemotherapy of moderate or high emetogenicity on the 6 days prior to cisplatin infusion or the 6 days following the cisplatin infusion~* Patient has vomited within 24 hours prior to cisplatin infusion~* Patient received or will receive radiation therapy to the abdomen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aprepitant (MK-0869) (Type: EXPERIMENTAL): None
- Standard Therapy (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intraoperative Dexamethasone on Post-op Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* undergoing bilateral cataract surgery~Exclusion Criteria:~* central corneal staining with fluorescein and/or a tear film osmolarity of greater than 340 in either eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Intracameral dexamethasone 9% + postoperative topical prednisolone acetate (Type: EXPERIMENTAL): dexamethasone intraocular suspension, 9% injected intracamerally at the time of cataract surgery + topical ophthalmic prednisolone acetate for 3 weeks post-operatively
- postoperative topical prednisolone acetate (Type: ACTIVE_COMPARATOR): topical ophthalmic prednisolone acetate for 3 weeks post-operatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 55 years of age~* Diagnosis of multiple sclerosis (MS)~* Relapsing MS: relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)~* At least 1 relapse during the previous 1 year or 2 relapses during the previous 2 years or a positive gadolinium-enhancing MRI scan in previous year~* Expanded disability status scale (EDSS) score of 0 to 5.5~Exclusion Criteria:~* Primary progressive MS~* Disease duration of more than 10 years in patients with an EDSS score of 2 or less~* Patients with an active chronic disease of the immune system other than MS~* Patients at risk of developing or having reactivation of hepatitis~* Patients with active systemic infections or with neurological findings consistent with PML

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- OMB 20 mg (Type: EXPERIMENTAL): Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1 ,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide- matching placebo, taken orally once daily
- TER 14 mg (Type: ACTIVE_COMPARATOR): Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Glucosamine/Chondroitin Sulfate to Patients Treatment With Osteoarthrosis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects have to read and sign the approved the Informed Consent form prior to any participation in the study.~* Male or female Subjects, aged upper to 40 years.~* Osteoarthritis of the knee confirmed by radiological examination.~* Visual analogue scale (VAS) \> 40 mm.~* Kellgren and Lawrence grade 1 to 3.~* Clinical diagnosis of pain and functional limitation.~Exclusion Criteria:~* History of significant trauma or surgery in the affected joint.~* Pregnant women, lactating or not using appropriate contraceptive method.~* History or presence of active rheumatic disease that may be responsible for secondary osteoarthritis.~* Severe inflammation of the joint confirmed by physical examination (excluding also erythrocyte sedimentation \<40mm/h and rheumatoid factor \<1:40).~* Body mass index \> 30.~* Hematologic abnormalities, liver, renal or metabolic functions which undermine the serious participation of the patient (at investigator's criteria).~* Systemic administration and/or intra-articular corticosteroids in the last 3 months.~* Have made use of glucosamine and/or chondroitin.~* Lequesne index of \> 12.~* Arthroplasty in the affected joint.~* Use of narcotic analgesics.~* Any condition that, in the opinion of the investigator, renders the patient unable to participate in the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cosamin DS® (Type: ACTIVE_COMPARATOR): glucosamine hydrochloride 500 mg and chondroitin sulfate 400 mg (Cosamin DS®, Nutramax Laboratories).~The medication was supplied as capsules, with the daily dose of 3 capsules.
- Glucosamine/ chondroitin sulphate (Type: EXPERIMENTAL): Glucosamine hydrochloride 500 mg and chondroitin sulphate 400 mg association (Eurofarma) T.I.D. before each meal The medication was supplied as capsules, with the daily dose of 3 capsules.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Imaging Airway Liquid Absorption in Cystic Fibrosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult healthy control arm:~  * subjects 18 years old or older without a diagnosis of lung disease.~* Pediatric CF arm:~  * subjects 6-14 years with a diagnosis of cystic fibrosis as determined by sweat test or genotype~ * subjects who are clinically stable as determined by the pediatrician co-investigator~ * subjects must have a previously demonstrated ability to perform reproducible pulmonary function testing based on previous clinical visits.~* Females in all groups who are of child-bearing potential will need to have a negative urine pregnancy test.~Exclusion Criteria:~* Adult healthy control arm:~  * FEV1%p \< 80% of predicted~ * nursing mother~ * positive urine pregnancy test or unwilling to test~ * cigarette smoker (regular smoking within 6 months of study).~* Pediatric CF arm:~  * FEV1%p \< 40% of predicted~ * nursing mother~ * positive urine pregnancy test for females of childbearing potential~ * unable or unwilling to comply with test procedure~ * cigarette smoker (regular smoking within 6 months of study).~ * Subjects unable to lie recumbent without moving for the 80 minute imaging period will be excluded.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- CF pediatric (Type: EXPERIMENTAL): In the pediatric arm 10 CF subjects ages 6-14 will perform absorptive clearance scans at baseline and at t=2 years.
- Controls adult (Type: EXPERIMENTAL): In the adult control arm 10 healthy adult subjects will perform a single absorptive clearance scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hysterectomy by Transabdominal Laparoscopy or NOTES

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All women aged 18 to 70 years regardless of parity, with a non-prolapsed uterus in need of a hysterectomy for benign indication~* Written informed consent obtained prior to surgery~Exclusion Criteria:~* History of rectal surgery~* Suspected rectovaginal endometriosis~* Suspected malignancy~* History of pelvic inflammatory disease, especially prior tubo-ovarian or pouch of Douglas abscess~* Active lower genital tract infection e.g. Chlamydia, N. gonorrhoeae~* Virgo~* Pregnancy~* Failure to provide written informed consent prior to surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- vNOTES hysterectomy (Type: EXPERIMENTAL): vaginal Natural Orifice Transluminal Endoscopic Surgery
- LSC hysterectomy (Type: ACTIVE_COMPARATOR): Laparoscopic hysterectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Ascorbic Acid Administration in Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* To be 18 years and older~* No smoking~* No history of bleeding disorder~* No history of favism~* No history of uterus, ovary, cervical cancer~Exclusion Criteria:~* Need to injection of vasopressor drugs~* Surgeon disagreement

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- vitamin C (Type: EXPERIMENTAL): Intervention patients will be received double dose of Ascorbic acid via intravenous injection
- Control (Type: NO_INTERVENTION): Control patients will not be received any intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participant 18 to 80 years of age with Mixed Hyperlipidemia with LDL-C between 130 and 190 mg/dL and Triglycerides between 150 and 500 mg/dL~Exclusion Criteria:~* Pregnant or lactating women, or women intending to become pregnant~* Diabetes mellitus that is poorly controlled, newly diagnosed, or taking new or recently adjusted antidiabetic therapy (with the exception of ± 10 units of insulin)~* Human immunodeficiency virus (HIV) positive~* Any of the following within the past 3 months: heart attack, stoke, heart bypass surgery, unstable angina, angioplasty~* Active or chronic liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- MK-0524B 2g/20 mg (Type: EXPERIMENTAL): Co-administration of one tablet of MK-0524A (Extended Release \[ER\] niacin/laropiprant \[LRPT\] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks
- MK-0524B 2g/40mg (Type: EXPERIMENTAL): Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks
- Atorvastatin 10 mg (Type: ACTIVE_COMPARATOR): Atorvastatin 10 mg, orally, once daily for 12 weeks
- Atorvastatin 20 mg (Type: ACTIVE_COMPARATOR): Atorvastatin 20 mg, orally, once daily for 12 weeks
- Atorvastatin 40 mg (Type: ACTIVE_COMPARATOR): Atorvastatin 40 mg, orally, once daily for 12 weeks
- Atorvastatin 80 mg (Type: ACTIVE_COMPARATOR): Atorvastatin 80 mg, orally, once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be ambulatory male subjects ≥ 55 years to ≤ 90 years of age~* Must have a BMD T score ≤ -2.50 at the spine or hip, or BMD T score ≤ -1.50 at the spine or hip and a history of fragility nonvertebral fracture or vertebral fracture.~Exclusion Criteria:~* A BMD T score ≤ -3.50 at the hip,~* History of hip fracture~* Severe metabolic bone diseases~* Significant laboratory abnormalities~* Recent treatment with agents affecting bone metabolism

- Gender: MALE
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Romosozumab (Type: EXPERIMENTAL): Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injections once a month for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be currently receiving aspirin therapy alone or in combination with a thienopyridine per national or local dosing recommendation~* Have been hospitalized for symptoms suggestive of acute coronary syndrome that lasted at least 10 minutes at rest and occurred 48 hours or less before going to the hospital~Exclusion Criteria:~* Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding~* Need for continued anticoagulant therapy~* Significant renal impairment or known significant liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban 2.5 mg bid (Type: EXPERIMENTAL): One 2.5 mg rivaroxaban tablet twice daily for up to 6 months
- Rivaroxaban 5 mg bid (Type: EXPERIMENTAL): One 5 mg rivaroxaban tablet twice daily for up to 6 months
- Placebo (Type: PLACEBO_COMPARATOR): One placebo tablet twice daily for up to 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Chemotherapy for Potentially Resectable Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 -75~* Histologically or cytologically proven in operable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction)~* ECOG performance status ≦2~* Tumor stage T3/4NxM0~* No distant metastasis (M0)~Exclusion Criteria:~* History of hypersensitivity to fluoropyrimidines, Tegafur，Gimeracil and Oteracil Potassium Capsules , capecitabine, oxaliplatin or the ingredients of this product~* Inadequate hematopoietic function： WBC≦4,000/mm3; ANC≦2,000/mm3; Platelet≦100,000/mm3~* Inadequate organ function which is defined as below:~Total bilirubin \>2 pper limit of normal range (ULN); ALT / AST \> 2.5 upper limit of normal range (ULN) (\>5.0 x ULN if hepatic metastasis); serum creatinine \> 1.2 mg/dL, and Ccr \> 60 ml/min (estimated by Cockcroft-Gault formulation);~* Symptomatic peripheral neuropathy~* Receiving a concomitant treatment with other fluoropyrimidines~* Pregnancy or lactation women, or women with suspected pregnancy or men unless using a reliable and appropriate contraceptive method.~* Mental status is not fit for chemotherapy therapy presence of serious concomitant illness which might be aggravated by study medication:~* Active cardiac disease e.g. decompensate myocardial infarction within the 6-month period preceding entry into the study.~* History of ventricular arrhythmia or congestive heart failure.~* Significant co-morbid medical conditions, including, but not limited to, Chronic obstructive pulmonary disease, interstitial pneumonia ,pulmonary fibrosis, heart failure, renal failure, hepatic failure, haemorrhagic peptic ulcer, mechanical or paralytic ileus, or poorly controlled diabetes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- postoperative chemotherapy,SOX (Type: ACTIVE_COMPARATOR): None
- Perioperative chemotherapy,SOX (Type: EXPERIMENTAL): None
- Perioperative chemotherapy,XELOX (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants aged ≥18 years~* Participants with suspected or known CAD based on signs and/or (typical or atypical) chest pain who have routine CA without intervention or CTA within 4 weeks around gadobutrol-enhanced CMRI~* Willingness to undergo stress/rest CMRI and to follow directions and complete all study procedures~* Women of childbearing potential (e.g. age \< 60y, no history of surgical sterilization or hysterectomy): use of contraception and a negative pregnancy test~Exclusion Criteria:~* Suspected clinical instability or unpredictability of the clinical course during the study period~* Contraindication to the cardiac MRI examination (e.g. inability to hold breath; severe claustrophobia, metallic devices such as pace makers)~* History of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents according to the investigator's assessment / judgment~* Estimated glomerular filtration rate (eGFR) value \<30 mL/min/1.73 m\^2 derived from a serum / blood creatinine result within 2 weeks prior to gadobutrol injection. Any participant on hemodialysis or peritoneal dialysis is excluded from enrollment.~* Acute renal insufficiency~* Coronary artery bypass grafting (CABG)~* Acute myocardial infarction (\< 14 days prior to inclusion), unstable angina / acute coronary syndrome, severe congestive heart failure~* Irregular heart rhythm~* Condition that precludes the safe administration of pharmacological stressor according to the respective approved label such as sinus node disease, 2nd or 3rd degree atrioventricular block, obstructive lung disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gadobutrol 0.1 mmol/kg body weight (Type: EXPERIMENTAL): Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete